» Articles » PMID: 22427855

In Vitro Characterization of a Nineteenth-century Therapy for Smallpox

Overview
Journal PLoS One
Date 2012 Mar 20
PMID 22427855
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

In the nineteenth century, smallpox ravaged through the United States and Canada. At this time, a botanical preparation, derived from the carnivorous plant Sarracenia purpurea, was proclaimed as being a successful therapy for smallpox infections. The work described characterizes the antipoxvirus activity associated with this botanical extract against vaccinia virus, monkeypox virus and variola virus, the causative agent of smallpox. Our work demonstrates the in vitro characterization of Sarracenia purpurea as the first effective inhibitor of poxvirus replication at the level of early viral transcription. With the renewed threat of poxvirus-related infections, our results indicate Sarracenia purpurea may act as another defensive measure against Orthopoxvirus infections.

Citing Articles

Monkeypox: a re-emergent virus with global health implications - a comprehensive review.

Naga N, Nawar E, Mobarak A, Faramawy A, Al-Kordy H Trop Dis Travel Med Vaccines. 2025; 11(1):2.

PMID: 39810237 PMC: 11734370. DOI: 10.1186/s40794-024-00237-w.


Natural Immunomodulatory Agents as a Complementary Therapy for Poxviruses.

Ali S, Salama A Adv Exp Med Biol. 2024; 1451:337-354.

PMID: 38801589 DOI: 10.1007/978-3-031-57165-7_22.


Emergence of monkeypox: a worldwide public health crisis.

Shabaaz Begum J, Ngangom L, Semwal P, Painuli S, Sharma R, Gupta A Hum Cell. 2023; 36(3):877-893.

PMID: 36749539 PMC: 9903284. DOI: 10.1007/s13577-023-00870-1.


Antiviral Potential of Melissa officinalis L.: A Literature Review.

Behzadi A, Imani S, Deravi N, Mohammad Taheri Z, Mohammadian F, Moraveji Z Nutr Metab Insights. 2023; 16:11786388221146683.

PMID: 36655201 PMC: 9841880. DOI: 10.1177/11786388221146683.


Traditional medicinal plants used for treating emerging and re-emerging viral diseases in northern Nigeria.

Abubakar I, Kankara S, Malami I, Danjuma J, Muhammad Y, Yahaya H Eur J Integr Med. 2022; 49:102094.

PMID: 36573184 PMC: 9760313. DOI: 10.1016/j.eujim.2021.102094.


References
1.
Chang H, Jacobs B . Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology. 1993; 194(2):537-47. DOI: 10.1006/viro.1993.1292. View

2.
Bolken T, Hruby D . Tecovirimat for smallpox infections. Drugs Today (Barc). 2010; 46(2):109-17. DOI: 10.1358/dot.2010.46.2.1437244. View

3.
Wollenberg A, Engler R . Smallpox, vaccination and adverse reactions to smallpox vaccine. Curr Opin Allergy Clin Immunol. 2004; 4(4):271-5. DOI: 10.1097/01.all.0000136758.66442.28. View

4.
Miles D, Kokpol U, Zalkow L, Steindel S, Nabors J . Tumor inhibitors. I. Preliminary investigation of antitumor activity of Sarracenia flava. J Pharm Sci. 1974; 63(4):613-5. DOI: 10.1002/jps.2600630427. View

5.
Yang G, Pevear D, Davies M, Collett M, Bailey T, Rippen S . An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol. 2005; 79(20):13139-49. PMC: 1235851. DOI: 10.1128/JVI.79.20.13139-13149.2005. View